Jan. 15 at 4:06 AM
$BNTX Across BioNTech’s cancer immunotherapies and related agents, side effects cluster into patterns familiar from other modern cancer drugs.
Frequent but usually low‑grade effects:
Fatigue, headache, muscle aches, chills, low‑grade fever.
Injection‑site pain, redness, or swelling for vaccine‑type agents.
Immune‑related toxicities (more serious):
With CTLA‑4 or other checkpoint‑modulating antibodies, high rates of immune‑related adverse events such as colitis (diarrhea), hepatitis (liver inflammation), pneumonitis (lung inflammation), and endocrinopathies (thyroid, adrenal, pituitary problems).
In one phase 3 trial of BioNTech’s CTLA‑4 antibody gotistobart, about 60% of patients experienced immune‑related adverse events and 13% discontinued treatment due to treatment‑related side effects.
Oncology‑specific concerns:Severe or life‑threatening events do occur but are tracked, graded, and managed under trial protocols
